Stocksigma LogoStocksigma Logo

Bal Pharma Reports Zero Deviation in Warrant Proceeds Utilization

Bal Pharma confirmed no deviation or variation in the utilization of proceeds raised via preferential convertible warrants for the quarter ended 30th

Bal Pharma Reports Zero Deviation in Warrant Proceeds Utilization

Bal Pharma Ltd · Others (Uncategorized) · 11 Nov 2026, 11:58 pm

Bal Pharma Reports Zero Deviation in Warrant Proceeds Utilization Bal Pharma confirmed no deviation or variation in the utilization of proceeds raised via preferential convertible warrants for the quarter ended 30th Sep'26. The company allotted warrants on 7th Sep'26, receiving upfront subscription proceeds of ₹2.10 cr (25% of the total ₹8.40 cr issue size at ₹21 per warrant). The capital is earmarked for setting up a greenfield API manufacturing facility at Yadgiri, Karnataka. As of 30th Sep'26, the entire ₹2.10 cr received remains unutilized.

Original exchange filing (PDF)

More announcements from Bal Pharma Ltd

All Bal Pharma Ltd announcements